TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of Post-hospitalization Interventions to Improve Physical Function in Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Admitted to the University of Texas Medical Branch (UTMB) ACE unit with an admitting diagnosis of congestive heart failure, respiratory infection, kidney/urinary tract infection, or metabolic disorder; or other condition that will allow a subject to participate in the study after patient review~* Aged 65 years or older~* Self-reported ability (with or without the aid of an assistive device) to walk across a small room two weeks prior to hospitalization~* Lives within 30 miles of UTMB~* Can stand without assistance at the time of pretesting~* Presents no medical contraindication to wearing a loose fitting velcro strap for the accelerometer on one ankle~* Score ≥26 on the 30-item Mini Mental State Examination or alert and oriented X3 by physician on H\&P~* Is discharged to home at ACE unit discharge.~Exclusion Criteria:~* Nursing home resident or hospice patient~* Uncontrolled blood pressure (systolic \>150, or diastolic \> 100)~* History of stroke with motor disability~* Glomerular filtration rate (GFR) \<30 mL/min/1.73m2 or evidence of kidney disease or failure~* Liver disease ( aspartate aminotransferase (AST) /Alanine transaminase (ALT) 2 times above the normal limit, hyperbilirubinemia)~* Recent (within 3 months) treatment with anabolic steroids~* Any other condition or event considered exclusionary by the PI and faculty physician~* Planned or elective hospitalization within 30 days of discharge~Additional Exclusion Criteria for Subjects Randomized to the Testosterone Group~* Breast or prostate cancer~* Palpable prostate nodule or induration or prostate specific antigen (PSA) ≥ 4 ng/ml~* PSA ≥ 3 ng/ml in men at high risk of prostate cancer, such as African Americans or men with first-degree relatives with prostate cancer~* Hematocrit ≥ 50%~* Decompensated heart failure as determined by a physician

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo Supplement (Type: PLACEBO_COMPARATOR): Daily placebo supplement for 30 days after discharge.
- Nutritional Supplement (Type: EXPERIMENTAL): Daily nutritional supplement for 30 days after discharge.
- In-home exercise + placebo (Type: EXPERIMENTAL): in-home exercise 3 times a week and daily placebo supplement for 30 days after discharge.
- In-home exercise + nutrition (Type: EXPERIMENTAL): in-home exercise 3 times a week and daily nutritional supplement for 30 days after discharge.
- Testosterone (Type: EXPERIMENTAL): Single testosterone injection within 24 hours of hospital discharge.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Sofosbuvir/Ledipasvir ± Ribavirin in Japanese Participants With Chronic Genotype 1 HCV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Body weight ≥ 40 kg~* HCV RNA ≥ 10\^5 IU/mL at screening~Exclusion Criteria:~* Current or prior history of any clinically-significant illness (other than HCV)~* Pregnant or nursing female or male with pregnant female partner~* Chronic liver disease of a non-HCV etiology~* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDV/SOF (treatment naive) (Type: EXPERIMENTAL): Treatment-naive participants will receive LDV/SOF for 12 weeks.
- LDV/SOF+RBV (treatment naive) (Type: EXPERIMENTAL): Treatment-naive participants will receive LDV/SOF plus RBV for 12 weeks.
- LDV/SOF (treatment experienced) (Type: EXPERIMENTAL): Treatment-experienced participants will receive LDV/SOF for 12 weeks.
- LDV/SOF+RBV (treatment experienced) (Type: EXPERIMENTAL): Treatment-experienced participants will receive LDV/SOF plus RBV for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fasting LDL-C ≥100 mg/dL~* High cardiovascular risk (diagnosis of HeFH and/or ASCVD)~* Be on maximally tolerated lipid-modifying therapy (LMT), including maximally tolerated statin either alone or in combination with other LMTs~Exclusion Criteria:~* Total fasting triglyceride ≥500 mg/dL~* Renal dysfunction or nephrotic syndrome or history of nephritis~* Body Mass Index (BMI) ≥50kg/m2~* Significant cardiovascular disease or cardiovascular event in the past 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- bempedoic acid (Type: EXPERIMENTAL): bempedoic acid 180 mg/day
- Placebo (Type: PLACEBO_COMPARATOR): Placebo control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced NSCLC~* Prior treatment with and failure of at least one regimen of chemotherapy and erlotinib or gefitinib~* Prior treatment with no more than two chemotherapy regimens, including adjuvant treatment~* Measurable disease~Exclusion Criteria:~* Chemotherapy, radiotherapy, biological or investigational agents within 4 weeks of baseline disease assessment~* Patients who lack of tolerance of erlotinib therapy~* Patients with known brain Metastases~* Patients with demonstrated history of or presence of interstitial lung disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: G-EO Gait Rehabilitation Training in Progressive Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-64 years~* Confirmed diagnosis of Primary or Secondary Progressive Multiple Sclerosis (this will be confirmed by the referring physician)~* EDSS 4.0-7.522~* Stable course of disease-modifying therapy over the past 6 months~* Asymptomatic (i.e., no underlying cardiovascular disease)~* Physician approval for exercise~* Willingness to visit the IU Health Neurosciences Center for testing and training~Exclusion Criteria:~* Pregnancy~* Current use of dalfampridine (Ampyra®)~* Conventional physical therapy or G-EO training within the past 6 months~* Height \<1m or \>2m~* Body weight \>150 kg~* Contraindications to G-EO gait training (e.g., bone instability)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Conventional Physical Therapy (Type: ACTIVE_COMPARATOR): Conventional physical therapy (CPT): CPT sessions will involve a 3-5 minute warm-up, stretching, progressive strength training exercises, and gait and balance training.40-43 Additional strategies for home exercises, energy conservation, fall prevention, and appropriate assistive devices (i.e., orthotics) will be provided.
- End-Effector Robotic Training (Type: EXPERIMENTAL): G-EO training: Using the G-EO System, participants will be secured with the appropriate sized harness and attached to an overhead body-weight support system, with feet secured to pressure sensitive footplates. Each session will begin with a 3-5 minute warm-up in the continuous passive mode (cadence \~40-45 steps/minute). The participant will then be transitioned into the adaptive training phase for practicing repetitive floor walking and stair climbing for up to 30 minutes. During this phase, the force produced by the robot is modulated to support the effort of the patient in producing a typical walking pattern.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Connecting Healthy Women: Examining the Effect of an Intervention From the Effect of Being Reachable

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women between the ages of 18 and 39~* Women newly enrolled in one of the state-wide Medicaid health plans (University Family Care)~* Women who are ambulatory~* Women who are community-dwelling~Exclusion Criteria:~* Women not between the ages of 18 and 39~* Women not newly enrolled in one of the state wide Medicaid health plans (University Family Care)~* Women who are not ambulatory~* Women who are not community dwelling

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: t

Study Arms:
- Control Group (Type: NO_INTERVENTION): Each month all newly enrolled female health plan members will have an equal chance of being randomly picked by the health plan (according to a randomization scheme provided by the study team) to be invited to contact and work with a Community health worker. Those not invited will constitute the usual care control group.
- Intervention Group (Type: OTHER): Each month all newly enrolled female health plan members will have an equal chance of being randomly picked by the health plan (according to a randomization scheme provided by the study team) to be invited to contact and work with a Community health worker in the intervention group.~The intervention group will be made up of two sub groups. The group of individuals who accept the invitation to participate (IG1) in the intervention and receive it, and those randomized to the intervention group but who reject the opportunity to participate (IG2).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have a clinical diagnosis of CTCL (mycosis fungoides), Stage IA, Stage IB, or Stage IIA.~* Subjects must have a minimum of three (3) evaluable, discrete lesions.~* Subjects must be willing to refrain from sunbathing for the duration of the study.~Exclusion Criteria:~* History of sun hypersensitivity and photosensitive dermatoses including porphyria, systemic lupus erythematosus, Sjögren's syndrome, xeroderma pigmentosum, polymorphous light eruptions or radiation therapy within 30 days of enrolling.~* Pregnancy or mothers who are breast feeding.~* Males and females not willing to use effective contraception.~* Unhealed sunburn.~* Subjects receiving topical steroids or other topical treatments for CTCL within 2 weeks.~* Subjects receiving systemic steroids, nitrogen mustard, psoralen UVA radiation therapy (PUVA), narrow band UVB light therapy (NB-UVB) or carmustine (BCNU) or other systemic therapies for CTCL within 3 weeks of enrollment.~* Subjects with significant history of systemic immunosuppression due to drugs or infection with HIV or HTLV 1.~* Subjects taking other investigational drugs or drugs of abuse within 30 days of entry into this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SGX301 (Type: ACTIVE_COMPARATOR): Three treatment cycles, each six (6) weeks followed by a two (2) week rest period. Treatment uses 0.25% SGX301 in USP Hydrophilic Ointment (or placebo) applied twice per week followed by fluorescent light therapy.~Cycle 1: Patients randomized 2:1 to active/placebo will have three (3) index lesions treated and evaluated.~Cycle 2: All patients will have three (3) index lesions treated and evaluated with active SGX301 ointment.~Cycle 3: All patients will be given the opportunity to enter an open-label cycle of active SGX301 ointment treatment for all lesions (index and non-index).
- Placebo (Type: PLACEBO_COMPARATOR): Placebo ointment is indistinguishable from ointment containing active SGX301 and is only used in Cycle 1. Treatment paradigm (ointment application and fluorescent light therapy) is identical.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Parent-Child Interaction Therapy With Autism Spectrum Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~i. Outpatients between 2 years, 6 months and 6 years, 11 months of age; ii. Diagnosis of Autistic Disorder, Pervasive Developmental Disorder Not Otherwise Specified, or Asperger's Disorder based upon the Autism Diagnostic Observation Schedule and clinical evaluation by Diagnostic and Statistical Manual of Mental Disorders IV criteria; iii. Males and females; iv. Mental Age\>30 months based upon the Stanford-Binet V or Mullens \[to insure that the child possesses enough expressive language to offer opportunities for the parent to learn verbal reflection skills and that child is able to understand time out\]; v. Eyberg Child Behavior Inventory score greater than or equal to 120; vi. Behavior Assessment System for Children Externalizing Problem Scale T-score \>65; vii. Care provider who can reliably bring subject to clinic visits, can attend weekly PCIT sessions, can provide trustworthy ratings and interact with subject on a regular basis.~Exclusion Criteria:~i. Unstable use of psychotropic medications (no changes in dose for at least two months and no plans to change dose during the course of the study); ii. Unstable use of dietary supplements (e.g., casein-gluten free diet)(no changes in supplement dose for at least two months and no plans to change douse during the course of the study); iii. Prior involvement in PCIT or currently receiving parent training. iv. Extremely severe behavioral concerns that require immediate treatment

- Gender: ALL
- Minimum Age: 30 Months
- Maximum Age: 83 Months
- Healthy Volunteers: f

Study Arms:
- Parent Child Interaction Therapy (Type: EXPERIMENTAL): Families will either receive Parent Child Interaction Therapy or be placed on a wait-list control group
- Wait list control (Type: NO_INTERVENTION): Families will wait 18 weeks for treatment, serving as controls.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Of Telemedicine Consultation at Home For Older Adults

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Member of the Strong Health Geriatrics Group practice~* Consent to participate~* Resident of facility with telemedicine established~Exclusion Criteria:~- None

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: None): Group without access to telemedicine in the home for acute care issues.
- Telemedicine care (Type: None): Cohort with access to telemedicine in the home for acute care issues.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MRI Results in Dupuytren's Contracture Before and After Injection With Xiaflex

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has a diagnosis of Dupuytren's Disease affecting only the metacarpophalangeal joint of the 4th or 5th finger.~* Subject has only one finger affected by the disease.~* Patients will be 35 years of age of older.~* Patients will be able to read, speak, and understand English or have available adequate translation assistance and be able to provide voluntary written consent to participate.~Exclusion Criteria:~* Female patients who are nursing or pregnant, or plan to become pregnant during the treatment phase.~* Patient has a chronic muscular, neurological or neuromuscular disorder that affects the hands.~* Patient has known allergy to collagenase or any other excipient of Xiaflex.~* Patient has received any collagenase treatments before the first dose of Xiaflex.~* Patient with abnormal coagulation, including patients who have received anticoagulant medications other than low-dose aspirin within 7 days of the injection.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- XIAFLEX (Type: OTHER): XIAFlEX

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be at least 18 years old~* Must have measurable or detectable ovarian, fallopian or primary peritoneal cancer~* Must have been treated previously with carboplatin, cisplatin or another organoplatinum compound~Exclusion Criteria:~* Women who are pregnant or nursing~* History of congenital long QT syndrome~* Active bleeding or at risk of a bleeding disorder~* Other significant medical condition or history of medical condition which may put the patient at risk

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- gemcitabine (Type: ACTIVE_COMPARATOR): None
- Gemcitabine + pazopanib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and female subjects~* Aged 65 to 85 years~Additional Inclusion Criteria for the extension Stage:~* Receipt of all 3 doses of C difficile vaccine (100 µg or 200 µg antigen dose level) in the original portion of the study.~Exclusion Criteria:~* Proven or suspected prior episode of Clostridium difficile associated diarrhea~* Unstable chronic medical condition~* Disease requiring significant change in therapy or hospitalization for worsening disease within 8 weeks before receipt of study vaccine~* Serious chronic disorders~* Congenital or acquired immunodeficiency disorders~* Rheumatologic disorders or other illnesses requiring chronic treatment with known immunosuppressant medications.~* Active or treated leukemia or lymphoma or bone marrow disorder~* Any contraindication to vaccination or vaccine components including previous anaphylactic reaction to any vaccine or vaccine-related components~Additional Exclusion Criteria for the Extension Stage:~* Subjects originally randomized to placebo during the original portion of the study.~* Subjects who have already completed Visit 9 prior to study unblinding.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Low-dose C. difficile Vaccine (accelerated schedule) (Type: EXPERIMENTAL): None
- High-dose C. difficile Vaccine (accelerated schedule) (Type: EXPERIMENTAL): None
- Placebo (accelerated schedule) (Type: PLACEBO_COMPARATOR): None
- Low-dose C. difficile Vaccine (non-accelerated schedule) (Type: EXPERIMENTAL): None
- High-Dose C. difficile Vaccine (non-accelerated schedule) (Type: EXPERIMENTAL): None
- Placebo (non-accelerated schedule) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete